The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
|
3 min read